A case of acute lymphoblastic leukemia (ALL) was encountered in which the two clonal y T-cell receptor gene (TCRy) rearrangements found in bone marrow (BM) samples at relapse both differed from the single clonal TCRy rearrangement present in BM obtained at diagnosis 5 years previously.
In contrast, two clonal lg heavy chain gene (IgH) rearrangements present at relapse were identical to those present at diagnosis. Comparison of the DNA sequences of the relapse TCRy rearrangements with that of the diagnostic TCRy rearrangement indicated that they must have been generated de novo from TCR-y loci in germline configuration. By polymerase chain reaction using clonotypic N-region oligonucleotide primers (N-PCR), cells bearing the diagnosis or ONFIGURATIONS of antigen receptor genes have C been used for a number of years as markers for detecting clonal proliferations of cells in lymphoid neoplasia.' More recently, tumor-specific DNA sequences within these rearrangements have been used as clonal markers for the sensitive monitoring of small numbers of residual neoplastic lymphoid cells after A variety of approaches have been taken for monitoring residual disease with these markers. All of these methods involve the application of the polymerase chain reaction (PCR) to assay the frequency in biopsy tissues of clonotypic nucleotide sequences that lie at the junction between segments in rearranged genes. These sequences are created at the time of gene rearrangement by the combined effect of variably sized small deletions from the ends of the rearranging segments and the insertion of short stretches of random sequence (so-called N-region sequences) between the segments before joining.
An important assumption in the use of junctional sequences for monitoring residual tumor is that these sequences are stable over the course of the disease. In this report, we describe a case of early pre-B-cell leukemia, also expressing a myeloid marker, for which this assumption did not hold. Rearrangements of the y T-cell receptor (TCRy) genes within leukemic cells of this case changed between clinical presentation and relapse, while rearrangements of Ig heavy chain (IgH) genes remained constant over the entire course of the disease. Relapse in this case occurred after an unusually long first remission, during which the bone marrow (BM) showed no molecularly detectable residual tumor. These findings suggest origin of this leukemia from a treatment-resistant progenitor cell with certain stem cell features.
MATERIALS AND METHODS
The patient was a 13-yearold female who presented with acute lymphoblastic leukemia (ALL) on November 13, 1980. She received induction and maintenance chemotherapy at the Dana Farber Cancer Institute on Dana Farber Protocol 80-01.' Relapse occurred in the BM on July 29, 1985 and a second remission was induced with intensive multiagent chemotherapy. A second relapse occurred on March 19,1987 and a third remission was induced with another course of intensive multi-agent chemotherapy. The patient died in third relapse on May 19,1987 .
Iliac crest BM aspirates obtained at diagnosis and during remissions and relapses were subjected to gradient centrifugation over Ficoll-Hypaque to isolate mononuclear cells and stored as single cell suspensions cryopreserved at -196°C in 10% dimethyl sulfoxide (DMSO).
Cryopreserved BM mononuclear cells obtained at time of diagnosis and relapse were thawed and examined for expression of various cell surface antigens using immunofluorescence flow cytometry. Aliquots containing 0.5 to 1 x lo6 cells were incubated for 30 minutes at 4°C with murine monoclonal antibodies (MoAbs) specific for Ia (I2), CD19 (B4), CDlO ( 5 9 , CD9 (JZ), CD20 (Bl), CD2 (Tll), CD33 (My9), CD13 (My7), and My8, washed twice, and incubated for an additional 30 minutes with goat antimouse IgG-fluorescein isothiocyanate (FITC; Tago, Burlingame, CA). After two additional washes to remove excess antibody, cells were fixed in 1% formaldehydeiphosphate-buffered saline (PBS) and analyzed for fluorescence reactivity using a Coulter EPICS V or Coulter ELITE (Coulter Electronics, Hialeah, FL). Cells obtained at diagnosis and first relapse were also examined for coexpression of CD19 and CD33 antigens using directly conjugated reagents (B4-FITC and My9-RD1) followed by two-color immunofluorescence analysis using the Coulter ELITE. All MoAb reagents were obtained from Coulter Immunology. Fluorescence reactivity was compared with negative control staining with nonreactive murine IgG. In each sample a total of 10,000 cells were Preparation of DNA. DNA was purified from aspirates or cell pellets by lysis in sodium dodecyl sulfate (SDS)-containing buffer followed by proteinase K digestion and phenol extraction."
The Southern analysis of BM DNA was performed by standard procedures essentially as described.' Blots were hybridized with J, ' or Jyl" probes that had been labeled with "P by hexamer priming."
PCR amplijication of tumor-specific antigen receptorgene rearrangements. The N-PCR procedure is outlined in Tycko et a1.' The procedure consists of two applications of PCR. In the first step, TCRy or IgH gene rearrangements present in diagnostic or relapse BM DNA are amplified using conserved V-and J-region primers and the PCR products are sequenced. In the second step, oligonucleotide primers are constructed to match the clonatypic junctional sequences (including N-region sequences) and used in a second application of PCR to assay for the tumor-specific gene rearrangements in BM samples. PCR was performed using nucleotides, buffer, and enzyme provided in the Perkin-Elmer Cetus Gene Amp Kit (Perkin-Elmer Cetus, Norwalk, CT) according to the specifications of the manufacturer. Each reaction contained 2 pg of starting DNA and 300 ng of each of the two oligonucleotide primers. Thermal cycling was as follows: denaturation for 1 minute at 94°C with an initial denaturation of 3.5 minutes; primer annealing at a temperature ranging from 55°C to 60°C and optimized for each set of oligonucleotide primers; chain elongation at 72°C for 1.5 minutes. The number of cycles was 30 in PCR runs in which a single set of primers was used and 40 (20 + 20) in runs in which two sets of nested primers were used sequentially. The sequences of the upstream Vy9 primers were: (outer primer) GGAATTCCAAAT-TCTTGGTTTA; (inner primer) CTGGCATTCCGTCAGGCA." The sequence of the upstream Vy4 primer was TTGCTGAAG-GAAGTACCGGC.I3 The sequence of the downstream Jyl primer used for generating PCR product for sequencing was CGTCGA-CAACAAGTGTTGTTCCAC." Sequences of tumor-specific TCRy junctional region primers were as shown in Fig 1A. The consensus V, and J, primers used to generate IgH gene rearrangement PCR product for sequencing were as described by Yamada et al. ' The sequences of clonotypic primers used in IgH N-PCR were as shown in Fig 1B. In PCR of the IgH rearrangement, the tumor specificity was contributed by the upstream primers: a clonotypic 5' upstream V, primer in the first round of PCR and a nested (more 3') upstream clonotypic primer, probably including both V, and N-insertion and/or D-region sequences, in the second round of nested PCR (Fig 1B) . Both rounds of nested PCR were performed using a downstream primer matching a sequence in the germline DNA 40 bp downstream of the 3' end of the J,, segment14 ( Fig 1B) .
PCR products were analyzed by electrophoresis on 1.3% to 1.5% agarose gels, followed by photographic documentation of ethidium bromide staining and, in the IgH PCR analysis, Southern transfer with blot hybridization to a DNA probe labeled with "P. The probe consisted of gel-isolated PCR product generated from a relapse tumor sample using the consensus IgH primers. Blots were hybridized and washed at high stringency essentially as described' and exposed from 2 to 48 hours on Kodak XAR5 film (Eastman Kodak, Rochester, NY).
The PCR products generated from diagnostic and relapse BM DNA using the Vy9/Jy and conserved V,/J, primer pairs were digested with restrictions enzymes (EcoRI and Sal I for TCRy products and Pst I and Sal I for the IgH products) and ligated into M13 sequencingvector. Multiple M13 clones were isolated and sequenced. Sequences that were found more than once in a set of clones were provisionally considered to represent clonal gene rearrangements. This finding was confirmed by the results of subsequent N-PCR using primers constructed to match these sequences.
Restriction endonucleases and M13 sequencing vectors were obtained from Bethesda Research Laboratories (BRL; Gaithersburg, MD). The Random Primers Labeling System (BRL) was used for generating '*P-labeled DNA probes. Sequencing reagents (Sequenase Kit) were obtained from United States Biochemical Corporation (USB; Cleveland, OH). Reagents for PCR (Gene Amp Kit) were obtained from Perkin-Elmer Cetus Corporation (Norwalk, CT).
Materials.

RESULTS
Southem blots of tumor DNA at diagnosis and relapse show changing TCR y rearrangements. To investigate antigen receptor gene rearrangements in the patient's tumor cells, DNA isolated from sequential BM aspirates spanning a 7-year clinical course was subjected to Southern blot analysis using TCRy and IgH J-region probes. Five aspirates were analyzed: one obtained at diagnosis, two obtained at different time points during a 5-year first remission, one obtained at first relapse, one obtained 2 years later at second relapse, and a third obtained 3 months before the patient's death.
When Southern blots of these DNAs were hybridized with the TCRy J-segment probe, a single rearranged band detected in the sample obtained at diagnosis was absent from both the first and second relapse samples, which instead showed a rearranged band at a slightly lower position (Fig 2A) . Although a single rearranged band was seen in relapse samples on Southern analysis, the greater intensity of this band relative to the germline band suggested that it might consist of two distinct but comigrating gene rearrangements derived from the two TCRy alleles. This was in fact confirmed by subsequent DNA cloning and sequencing of TCRy rearrangements in one of the relapse samples (see below).
The Southern blots used to prepare Fig 2A were then stripped and rehybridized with an IgH J-segment probe. The resulting autoradiogram showed two rearranged bands in similar positions in both the diagnostic and two relapse samples (Fig 2B) . These rearrangements were not detected in the two remission samples.
Southern blot analyses for TCRp gene rearrangements were also performed on each sample. No clonal rearrangements of this locus could be detected at any time during the clinical course (data not shown).
Ampl8cation and sequence analysis of TCR y rearrangements at diagnosis and relapse. The TCRy rearrangements present in diagnostic and second relapse samples were first amplified by PCR using a downstream oligonucleotide primer specific for the conserved 3' end of the Jyl and Jy2 segments and upstream primers specific for either the conserved 5' end of the VyI cluster" or for the 5' end of the Vy9 region.'' DNA from the diagnostic sample amplified more intensely with the VyI/Jy primer pair, while the second relapse sample amplified more intensely with the Vy9/Jy primer pair (not shown). This finding was consistent with the band locations of the TCRy rearrangements on Southern analysis with Hind111 digestion, which also suggested that the relapse samples might contain one or more Vy9-Jy rearrangements.'' The diagnostic VyIIJy PCR product and the second relapse sample Vy9/Jy PCR product were then cloned in M13 phage for DNA sequencing.
Four clones derived from the diagnostic sample were identical and showed Vy4 joined to Jy (Fig 1A) . The junctional sequence showed small exonucleolytic deletions into the 3' end of Vy4 and the 5' end of Jy and an interposed G/C-rich stretch of random nucleotides (N-
insertion). The clones derived from the relapse sample all showed Vy9 joined to Jy but fell into two groups with different junctional sequences (Fig 1A) . The differences were seen both in the extent of deletions into Vy9 and Jy and in the sequence of the N-insertion. This finding indicated that, as suspected from the relative band intensity, the single rearranged band seen on Southern analysis of thc relapse samples actually consisted of two distinct but comigrating Vy9-Jy rearrangements.
N-PCR analysis of the BM samples. We have previously reported a method for measuring minimal residual disease in patients with ALL in remission. This method uses PCR amplification of DNA within antigen receptor genes with clonotypic junctional, or "N-region," primers.' The procedure, which we refer to as N-PCR, has been shown to reliably detect as little as one tumor cell in 4 x 10' normal BM mononuclear cells.',"
To investigate the time of appearance of each of the TCRy gene rearrangements and evaluate the depth of the remissions, N-PCR was performed on each of the DNA samples. Clonotypic N-region primers were constructed based on the sequences in Fig 1A. A clonotypic primer for the IgH rearrangement was constructed based on sequence determined from multiple M13 clones containing PCR product generated from the DNA of the diagnostic sample using consensus V,, and J,, primers (Fig 1B) . N-PCR using the primer specific for the diagnostic TCRy rearrangement gave a product of the anticipated size in the diagnostic sample but gave no detectable product either in the remission or in the relapse samples (Fig 3A) . Conversely, N-PCR using a clonotypic primer specific for one of the relapse TCRy rearrangements yielded a product in both of the relapse samples but gave no detectable product in either the remission of the diagnostic samples (Fig 3B) . As expected, normal BM controls subjected to N-PCR did not yield detectable amplified product. 
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Consistent with the stability of the IgH rearrangements seen on Southern analysis, both the diagnostic and the relapse samples showed an amplified product when subjected to N-PCR using clonotypic primers specific for one of the relapse rearrangements ( Fig 3C) . As with the TCRy primers, the two first remission samples again showed no amplified product. In contrast, residual tumor was easily detectable in the third remission sample (May 19, 1987) . To allow quantitation of thc amount of residual tumor in remission samples, serial dilutions of tumor DNA wcrc examined in the same experiment. This experiment confirmed that the sensitivity of N-PCR extended to the single cell level (Fig 3C) . Thc absence of detectable amplified product in the first remission samples, in which a total of 4 X 10' cell-equivalents of DNA was examined, established an upper limit for the amount of residual tumor during first remission of less than one in 4 x 10' BM mononuclear cells.
Cells obtained by BM aspiration at diagnosis and at first and second relapse were subjected to flow cytometric analysis using a panel of MoAbs and polyclonal antibodies specific for B-cell, T-cell, and myeloid marker antigens (Fig 4) . The tumor cells were negative for T-cell markers A99 (polyclonal hetero T-cell) and CD2, but positive for the carly B-cell marker CD19. However, the cells were also negative for CALLA/CDlO and CD20, and positive for the mycloid antigcn My9/CD33. With the exception of an increasing degree of My9/CD33 Immunophenotype analysis. 
kb-
reactivity between first and second relapse, there appeared to be no significant change in the phenotype over the clinical course.
DISCUSSION
In the course of studies of minimal residual disease in patients with ALL we encountered a case with several interesting features. First, the patient had a prolonged clinical coursc, including a 5-year first remission. Second, the tumor cells showed a primitive phenotype, with both early pre-B and myeloid antigens. Third, the tumor cells showed changes in antigen receptor gene rearrangements between diagnosis and relapse. These changes were apparent on Southern blot analysis, which suggested that the clonal TCRy rearrangement present in the leukemic cells at diagnosis was rcplaced by a different rearrangement at first relapse and that this rearrangement persisted in the tumor cells at second rclapse. This conclusion was confirmed by sequencc analysis of PCR products amplified from the diagnostic and first relapse samples. The full extent of this replacement was indicated by N-PCR, which showed that the initial TCRy gene rearrangement could not be detected in any of 2 x 10' nucleated BM cells obtained during the first or second relapse. N-PCR also failed to detect one of the two relapse TCRy gene rearrangements in the diagnostic sample at a comparable level of sensi t ivi ty. DNA sequences deduced for the diagnostic and relapse TCRy gene rearrangements, together with the physical map of the human TCRy locus," indicated that the diagnostic and relapse rearrangements were unrelated. The diagnostic sample contained a Vy4-Jy rearrangement, while both TCRy gene rearrangements in the relapse samples were Vy9-Jy. Because Vy9 is the most J-proximal Vy segment and therefore lies downstream from Vy4 in the germline TCRy locus, the formation of a Vy4-Jy rearrangement would be expected to result in the deletion of the DNA containing Vy9. Consequently, neither of the relapse Vy9-Jy rearrangements could have been derived from the original Vy4-Jy rearrangement by V-region replacement. Rather, both relapse rearrangements must have been derived de novo from TCRy loci in germline configuration. This finding, in turn, suggests that the tumor cells present at relapse arose as the clonal progeny of a tumor stem cell that had both TCRy alleles in germline configuration.
The apparent stem cell features of the tumor progenitor cell in this case are consistent with the unusual immunophenotypic findings. These findings include presence of the early B-cell antigen CD19 in the absence of CALLAiCD10 and CD20-a phenotypic profile suggesting a pre-pre-B cell or early pre-B cell stage of differentiation. Furthermore, the tumor cells expressed the myeloid antigen My9/ CD33. The combination of CALLA-negativity and myeloid antigen expression is somewhat unusual in childhood ALL" and resembles phenotypes more often seen in infant null ALL, a neoplasm thought to derive from multipotent precursor cells." Similar evidence for an association between myeloid antigen expression and a stem cell etiology in ALL is provided by a recent study that described a higher incidence of coexisting B-lineage (IgH) and T-lineage (TCRP) antigen receptor gene rearrangements in those cases that displayed myeloid antigen.2' Also, an apparently distinct subclass of acute myeloid leukemia (AML) has been documented in which the tumor cells express both myeloid antigens and the lymphoid marker terminal deoxynucleotidyl transferase (TdT) and in which clonal TCR and IgH gene rearrangements are usually present.'* Interestingly, adults with ALL appear to have a poorer prognosis if their tumor cells express myeloid antigens."
Development of lymphoid tumors from some type of stem cell may not be uncommon. Occasional cases of lymphoma and chronic lymphocytic leukemia show changing antigen receptor gene rearrangements over time. 24 Furthermore, common ALLs often contain a multiplicity of For personal use only. on October 23, 2017. by guest www.bloodjournal.org From IgH gene rearrangements due to different de novo V-D-J joinings, consistent with outgrowth of several subclones from a lymphocyte-committed stem cell.*' Indeed, it is conceivable that most cases of ALL actually originate from a transformed lymphoid stem cell, but that a dominant subclone consistently overgrows any competing subclone and consequently persists throughout the course of the disease. In the present case, the patient experienced a deep first remission (less than one leukemic cell in 400,000 total nucleated BM cells, as indicated by N-PCR of IgH genes in two separate bone marrow aspirates). These low levels of residual disease corresponded with reasonably prolonged remissions, especially between diagnosis and the first relapse, a correlation also noted in other cases of ALL that we have examined retrospectively.6 It is possible that the profound reduction of tumor cells during the first remission resulted in the eradication of the subclone containing the first TCRy gene rearrangement while the transformed progenitor cell remained. Sometime during the first remission, this progenitor cell, which contained both TCRy alleles in germline configuration but which continued to express recombinase activity, gave rise to a second subclone carrying new TCRy rearrangements. The second remission was not as deep (reflected by the shorter remission) and the second subclone therefore survived through this remission to reemerge at the time of the subsequent relapse. This scenario would predict that the stem cell origin of certain tumors may be more likely to be shown in cases that relapse after more intensive therapy, greater cytoreduction, and possibly longer remissions.
The existence of tumors with certain stem cell features may have important implications for both the diagnosis and therapy of these neoplasms. With regard to diagnosis, the changes in antigen receptor gene rearrangements will obviously effect the ability to monitor residual disease by N-PCR or any related technique. In our experience with N-PCR primarily involving TCRy genes, changes in gene rearrangements have been limited to the present case. In fact, stable TCRy gene rearrangements have been noted in cases with numerous IgH rearrangements studied by Southern blotting. Nevertheless, it is clear from the present case that possible changes in gene rearrangements must be considered as a potential source of false-negative results in screening biopsy specimens for residual disease using these markers. Perhaps parallel analyses of remission samples for several antigen receptor gene rearrangements (eg, TCRy and IgH) should be used for this reason.
Other implications of stem cell tumors pertain to therapy. Hematopoietic stem cells are thought to be relatively resistant to cytotoxic agents, as reflected in the rapid repopulation of the BM by normal elements after high-dose chemotherapy for leukemia. If tumors with stem cell features represent a distinct subgroup of lymphoid neoplasms, it may be that these tumors are the most likely to recur after conventional therapy and therefore require more intensive treatment to achieve a cure.
